Share
Custom Manufacturing Industry podcast is an entrepreneurship and motivational podcast on all platforms, hosted by Aaron Clippinger. Being CEO of multiple companies including the signage industry and the software industry, Aaron has over 20 years of consulting and business management. His software has grown internationally and with over a billion dollars annually going through the software. Using his Accounting degree, Aaron will be talking about his organizational ways to get things done. Hi ...
…
continue reading
Manage episode 522116028 series 2739469
Content provided by Ben Comer. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Ben Comer or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
We love to hear from our listeners. Send us a message.
On this week's episode of the Business of Biotech, Dan Schmitt, President and CEO at Actuate Therapeutics, talks about building a company around elraglusib, a GSK-3β inhibitor for cancer. Dan describes his fast-fail approach to early product testing and development, using basket trials to evaluate chemotherapy combinations, and choosing pancreatic cancer as a lead program. He also talks about surviving an IPO during a brutal funding cycle for biotech, building lean teams and efficient operations, and potentially onshoring API in response to changing U.S. policy.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [email protected]
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Chapters
1. Meet Dan Schmidt And Actuate (00:00:00)
2. From Vet Clinic Roots To Big Pharma (00:01:16)
3. Scouting Academia For Spinouts (00:05:28)
4. Founding Actuate Around GSK3 Inhibitors (00:09:31)
5. Proving The Molecule Across Many Labs (00:13:05)
6. Why Pancreatic Cancer As Lead (00:16:26)
7. Safety, Specificity, And Mechanism (00:20:12)
8. The Unmet Need In Pancreatic Cancer (00:24:06)
9. Single Asset Strategy Pros And Cons (00:28:05)
10. Weathering A Brutal IPO Market (00:30:26)
11. Running Lean And Funding Smart (00:34:00)
12. Partnerships, CDMOs, And Supply Resilience (00:38:08)
13. Policy, Onshoring, And Risk Planning (00:41:46)
14. FDA Outlook And Survival Endpoints (00:44:59)
15. Market Green Shoots And Momentum (00:48:10)
16. Near-Term Milestones And What’s Next (00:50:35)
283 episodes
))
